## Previous exam questions in clinical research and epidemiology

Mean incidence of influenza in Norway in week 45 in 2009 was 14%. We may consider that the duration of influenza to be on the average 3 days. What was the mean prevalence of influenza during that week?

- a) 2.25%
- b) 4.5%
- c) 6%
- d) 14%

Mean incidence of influenza in Norway in week 8 in 2012 was 3%. We may consider that the duration of influenza to be on the average 5 days for that epidemic. What was the mean prevalence of influenza during that week?

- A) 2.1%
- B) 3%
- C) 6%
- D) 14%

Mean incidence of a virus epidemic in Trondheim in in a certain week was 6%. On the average 1.7% of the people were ill each day. What was the average duration of the disease?

A one day

- B two days
- C three days
- D Four days

The prevalence of diabetes has increased over the last decades. What are possible explanations for this increase?

- A) More people get diabetes.
- B) People who get diabetes live longer with the disease.
- C) Both A and B.
- D.) Neither A nor B.

What happens to the frequency of a disease if a new treatment prevents people from dying, but has no curative (= healing) effect?

A The prevalence of the disease will decrease (= go down)

- B The incidence of the disease will increase (= go up)
- C The prevalence of the disease will increase
- D The incidence of the disease will decrease

In a case-control study of the association between an exposure and a disease;

- A the controls should not be exposed
- B 10% of the controls should be exposed

C the controls should represent the distribution of the exposure in the population that the cases come from

D the controls should be matched to the cases so that the exposure is similar between cases and controls

How can confounding change the effect estimate (e.g. a relative risk) of a cohort study? The effect estimate

- A can become either too large or too small
- B can only become too large
- C will not change
- D will not change if the study is large enough

Compared to cohort studies, what is a major limitation of the case-control design in the study of a causal relation between a factor (= exposure) and a disease (= outcome)?

- A. A case-control study is more expensive and takes longer time
- B. There may be bias (= systematic error) in the measured presence or absence of the suspected factor (exposure)
- C. There may be bias (= systematic error) in the measured presence or absence of the resulting outcome (disease)
- D. It is difficult to identify (ascertain/skaffe) appropriate controls

The association between hypertension (high blood pressure) and stroke was examined in a cohort study. The study showed that the relative risk of stroke was 3 among people with hypertension, compared with people without hypertension. What is the correct interpretation of this result?

- A) People with hypertension had a 3 times higher probability of getting a stroke, compared with people without hypertension.
- B) When people with hypertension got a stroke, they had a 3 times higher probability of dying from the disease, compared with people without hypertension.
- C) The prevalence of stroke was 3 times higher among people with hypertension, compared with people without hypertension.
- D) The brain area affected in stroke patients was on average 3 times larger in people with hypertension, compared with people without hypertension.

A certain clinical study shows treatment 1 to be better to reduce the mortality (number of deaths) than treatment 2 for a certain disease with a p value (significance) of 10%. What does this mean?

- A The probability of dying of the disease with treatment 1 is 10% lower than with treatment 2
- B The number needed to treat the disease with treatment 1 instead of treatment 2, in order to reduce the number of deaths by one patient, is 10
- C The difference may be real, with a probability of 90%
- D The difference may be real, but only with a probability of 10%

The results of the study above were a little disappointing, as we like the significance level of a clinical study to be below 5% for the result to be useful. So the study power was calculated, and was found to be only 70% for the patient number and desired significance level of 5%. What does that mean?

A That only 70% of the patients would profit from treatment 1 over treatment 2

- B That 70% of the patients would survive with treatment 1, as opposed to only 30% with treatment 2
- C That there was only 70% probability of achieving a p value of 5%, even if the difference was real
- D That there was only 30% probability that the difference was real

Aclinical study of a certain disease, comparing treatment A with treatment B, found a difference in mortality between treatment A and treatment B (A<B) with a significance of <1%. What does that mean?

- A) That the mortality is reduced by  $\geq$  1% with treatment A compared to B
- B) That the study strength was 99%
- C) That this finding was almost certainly real (with a probability of ≥ 99%)
- D) That this finding was almost certainly random (with a probability of ≥ 99%)

A certain clinical study shows treatment 1 to be better to reduce the mortality (number of deaths) than treatment 2 for a certain disease with a p value (significance) of 5%. What does this mean?

- A The probability of dying of the disease with treatment 1 is 5% lower than with treatment 2
- B The number needed to treat the disease with treatment 1 instead of treatment 2, in order to reduce the number of deaths by one patient, is 5
- C The difference may be real, with a probability of 95%
- D The difference may be real, but only with a probability of 5%

For a treatment result to be significant, what is the customary limit for the p value?

A 2.5%

B <mark>5%</mark>

C 10%

D 20%

What is evidence based medical practice?

- A Practice that is founded in solid physiological experiments as evidence
- C Practice that takes into account both clinical studies, medical background knowledge and patients experience and preferences
- B Practice that is only founded in clinical studies
- D Practice that is founded on large epidemiological studies

Study power is a measure of the probability of proving a given hypothesis by a clinical study. What is the study strength dependent on?

- A Only study size
- B Only variability of the outcome variable
- C Only the desired significance level
- D All of the above

What does it mean that a study is controlled?

A The study is under the regulations of the FDA (Food and Drug Agency) or similar regulating bodies

B The study has a control group (for instance receiving no treatment or an established treatment)

- C The study is approved by the ethical committee
- D The study has a built in quality check system

The significance (p value) of a controlled study result, is often given as a percentage, for instance 5%. What does this mean?

- A The probability of the study result being true (non random) is 5%
- B The probability of the study result being wrong (random) is 5%
- C The study effect (difference in outcome between groups) is 5%
- D The study